RP105-Negative B Cells in Systemic Lupus Erythematosus
Author Information
Author(s): Syuichi Koarada, Yoshifumi Tada
Primary Institution: Saga University
Hypothesis
Targeting RP105-negative B cells may be a potential treatment for systemic lupus erythematosus (SLE).
Conclusion
RP105-negative B cells are involved in the pathophysiology of SLE and may serve as therapeutic targets.
Supporting Evidence
- RP105-negative B cells increase in the blood of patients with active SLE.
- These cells produce autoantibodies, including anti-dsDNA antibodies.
- Targeting RP105-negative B cells may help in treating SLE.
Takeaway
Some B cells in people with lupus don't have a special marker called RP105, and these cells can make harmful antibodies. Finding ways to target these cells might help treat lupus.
Methodology
The study involved analyzing B cells from patients with SLE and normal subjects using flow cytometry to assess the expression of RP105.
Limitations
The study primarily focuses on the role of RP105 in mice, and the findings in humans may not fully align.
Participant Demographics
The study involved patients with systemic lupus erythematosus and normal subjects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website